Renovaro Biosciences Inc (RENB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has a cash flow conversion efficiency ratio of 0.085x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.81 Million) by net assets ($-21.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Renovaro Biosciences Inc (RENB) balance sheet quality index to measure how much of total assets are equity-financed.
Renovaro Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Renovaro Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RENB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Renovaro Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Renovaro Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ISPD Network S.A.
PA:ALISP
|
2.953x |
|
Maral Overseas Limited
NSE:MARALOVER
|
0.606x |
|
Jentayu Sustainables Bhd
KLSE:5673
|
-0.071x |
|
Nova EYE Medical Ltd
AU:EYE
|
-0.144x |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
0.030x |
|
CompuLab Ltd
TA:CLAB
|
0.080x |
|
PJX Resources Inc
V:PJX
|
-0.754x |
|
VBX Ltd
AU:VBX
|
-13.513x |
Annual Cash Flow Conversion Efficiency for Renovaro Biosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Renovaro Biosciences Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RENB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $131.98 Million | $-10.97 Million | -0.083x | 0.00% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -87.59% |
| 2020-06-30 | $166.27 Million | $-10.46 Million | -0.063x | -27.99% |
| 2019-06-30 | $173.10 Million | $-8.51 Million | -0.049x | -79.83% |
| 2018-06-30 | $158.74 Million | $-4.34 Million | -0.027x | +96.44% |
| 2017-06-30 | $1.53 Million | $-1.18 Million | -0.768x | -133.26% |
| 2016-06-30 | $-637.40K | $-1.47 Million | 2.310x | +495.42% |
| 2015-06-30 | $3.48 Million | $-2.03 Million | -0.584x | -143.88% |
| 2014-06-30 | $-1.60 Million | $-2.13 Million | 1.331x | +126.81% |
| 2013-06-30 | $-51.27K | $-30.09K | 0.587x | -67.81% |
| 2012-06-30 | $-13.68K | $-24.95K | 1.823x | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more